Polygenic Risk Score Services Market Research Reveals Strong 16.4% CAGR Outlook Through 2030

The polygenic risk score services market is emerging as a rapidly expanding segment within the broader genomics and personalized medicine landscape. Driven by advances in genetic analysis and precision healthcare, this market is set to experience significant growth over the coming years. Below, we explore the market's projected size, key players, evolving trends, and the primary segments shaping its development.

Forecasted Growth and Market Size of the Polygenic Risk Score Services Industry
The polygenic risk score services market is anticipated to grow substantially, reaching a valuation of $3.11 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 16.4% during the forecast period. The surge in growth is fueled by several factors, including a wider clinical acceptance of risk stratification tools, an increasing incorporation of polygenic risk scores (PRS) into personalized medicine frameworks, and the expansion of preventive genomics initiatives. Additionally, there is a rising demand for platforms that enable genetic data interoperability, alongside enhanced regulatory clarity for genetic testing services. Trends like the adoption of advanced polygenic risk prediction algorithms, integration of PRS with clinical decision-making tools, and the rise of population-specific risk models further support this upward trajectory. The expansion of direct-to-consumer genetic risk services and heightened attention to data privacy and security also play important roles.

The polygenic risk score services market size has grown rapidly in recent years. It will grow from $1.45 billion in 2025 to $1.69 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to expansion of large-scale genotyping studies, increasing availability of genomic databases, growth in preventive healthcare initiatives, rising interest in genetic risk assessment, advances in statistical genetics methods.

Download a free sample of the polygenic risk score services market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28302&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Players Leading the Polygenic Risk Score Services Sector
Several prominent companies currently dominate the polygenic risk score services market. These include Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Illumina Inc., Endeavor Health Inc., Myriad Genetics Inc., The Broad Institute of MIT and Harvard, BGI Group, Invitae Corporation, 23andMe Holding Co., Color Health Inc., Genomics Ltd., Cogentech S.R.L., Gene by Gene Ltd., Our Future Health Ltd., Mapmygenome India Limited, Australian Genome Research Facility (AGRF) Ltd., Golden Helix Inc., Allelica Inc., Antegenes OÜ, and GeninCode Plc.

A notable development occurred in May 2024 when UK pharmaceutical company GSK Plc collaborated with Genomics Ltd. This partnership focuses on advancing genetic research and developing personalized therapies by leveraging polygenic risk scores. The goal is to improve clinical trial outcomes by more accurately selecting patients, which can reduce trial sizes and durations while enhancing the efficiency of drug development. Genomics Ltd. specializes in precision medicine and provides polygenic risk score services, making it a key player in this evolving market.

View the full polygenic risk score services market report:
https://www.thebusinessresearchcompany.com/report/polygenic-risk-score-services-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Driving Innovation in Polygenic Risk Score Services
Leading organizations in the polygenic risk score services market are increasingly prioritizing pharmacogenomics to refine personalized treatment approaches. Pharmacogenomics, which studies how genetic differences influence drug response, is critical for tailoring therapies to improve patient outcomes. For instance, in July 2025, UK-based health insurer Bupa introduced a new range of DNA-based tests aimed at delivering personalized health and wellness insights. These tests provide information on how patients might respond to medications and their risks for diseases such as cancer, diabetes, and heart disease. This encourages proactive healthcare management, early detection, and customized treatment, reducing adverse side effects and enhancing long-term health.

The shift toward integrating genetics into healthcare represents a broader move from reactive treatment models to preventive, precision health strategies. These developments not only empower patients to take control of their health but also enable more efficient clinical care and improved population health outcomes.

Detailed Segmentation of the Polygenic Risk Score Services Market
This market can be broken down into several key segments to better understand its scope and applications:

1) Service Type:
- Genotyping
- Sequencing
- Data Analysis
- Reporting
- Other Service Types

2) Application:
- Disease Risk Assessment
- Personalized Medicine
- Research
- Other Applications

3) End-User:
- Hospitals and Clinics
- Research Institutes
- Direct-to-Consumer
- Other End-Users

Further subcategories include:

Genotyping methods such as array-based genotyping, targeted genotyping, and high-throughput genotyping; sequencing techniques including whole genome sequencing (WGS), whole exome sequencing (WES), and targeted sequencing; data analysis services like polygenic risk prediction algorithms, bioinformatics and statistical analysis, and integration with electronic health records (EHR); reporting segments comprising clinical reports for healthcare providers, direct-to-consumer reports, and disease-specific risk stratification reports; along with other service types covering genetic counseling, data storage and cloud platforms, and PRS software and toolkits.

Together, these segments highlight the diversity within the polygenic risk score services market, reflecting its critical role in advancing personalized medicine, research, and clinical practice worldwide.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.